In 1993, for the first time, point mutations in the RET gene were described in patients with MEN 2A and FMTC [9,13] and in the subsequent year, a specific RET mutation (M918T) was associated with MEN 2B and sporadic MTC [21]. The gene discussed is RET; the disease is multiple endocrine neoplasia type 2A.